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30–35ml/min as stated in the present KDIGO clinical practice
guidelines may be too low.
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The Authors Reply: For patients with chronic kidney disease
stage 3 without evidence of bone or mineral disorder,
the Kidney Disease Improving Global Outcomes workgroup
recommended treatment for osteoporosis as in the general
population. Over 80% of women with osteoporosis have
chronic kidney disease stage 3 or 4 (ref. 1). Most of these
elderly patients with age-related chronic kidney disease are
not examined by nephrologists. In determining appropriate
therapy for osteoporosis, the reduction in hip fracture and,
potentially, in mortality, must be balanced against adverse
events. In the pivotal trials of zoledronic acid, a transient
increase in serum creatinine was noted in 1.3% of the
patients on the drug and in 0.4% on placebo in 3889
osteoporotic patients.2 In a study of 1065 patients with a
recent hip fracture, an increase in serum creatinine was seen
in 6.2% of patients on the drug and 5.6% on placebo. There
was a 28% reduction in overall mortality with the drug.3
As Dr Woo has written, there are some newer reports
of renal damage that have emerged from post-marketing
surveillance.4 However, the incidence of these adverse events
is still low, 18 per 100,000 per year, and most of the patients
had only a transient increase in creatinine. Thus, preventing
the devastating consequences of a hip fracture will usually
outweigh this small risk of kidney damage. To reduce the risk,
physicians should follow guidelines about infusion rates,
avoid volume depletion, or the administration of concomitant
nephrotoxic medications. In addition, using oral dosing may
help reduce this risk.
Once the kidney disease has progressed to chronic kidney
disease–mineral and bone disorder (which is not determined
by the estimated glomerular ﬁltration rate but by abnormal-
ities in calcium, phosphate, parathyroid hormone, or alkaline
phosphatase), there is very little evidence about either safety
or efﬁcacy because these patients were excluded from
the clinical trials. Therefore, we could not recommend the
use of these drugs in the Kidney Disease Improving Global
Outcomes guidelines. These patients must be treated on
an individual basis, and we agree that the possibility of
aggravated progression of renal disease should now be taken
into consideration.
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Hypophosphatemia in patients
with autosomal dominant
polycystic kidney disease: the role
of fibroblast growth factor 23 or
loss of sodium/phosphate
cotransporter?
To the Editor: We read with great interest the contribution
by Pavik et al.1 They reported increased ﬁbroblast growth
factor 23 (FGF23) and decreased serum phosphate levels in
autosomal dominant polycystic kidney disease (ADPKD), and
speculated the association between FGF23 and increased
renal phosphate excretion. We would like to suggest another
possible mechanism of hypophosphatemia in ADPKD
patients.
According to an in vivo study by Vogel et al.,2 the type II
sodium/phosphate cotransporter (NaPi-2) in the brush
border membrane (BBM) of proximal tubules has the central
role of renal phosphate (Pi) absorption. During progression
of ADPKD, the proximal nephron is damaged by the
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cystic changes, and epithelial proliferation and impaired
epithelia–matrix interaction result in a loss of BBM and
cellular interdigitation paralleled by the loss of NaPi-2.
Advanced renal damage was associated with phosphaturia,
suggesting functional insufﬁciency of tubular NaPi-2
reabsorption.
Therefore, there is a possibility that the loss of the NaPi-2
system in the proximal tubule BBM, as well as the elevated
FGF23 suppressing renal tubular phosphate reabsorption
and 1a-hydroxylase activity, might be involved in the
pathogenesis of increased renal phosphate excretion and
hypophosphatemia in patients with ADPKD. However,
further studies are necessary to elucidate what is exactly
responsible for the increased FGF23 secretion in ADPKD
and the correlation between the increased FGF23 and the
loss of NaPi-2. Whether the increase in serum FGF23 in
patients with ADPKD precedes or follows the decrease
in glomerular ﬁltration rate should also be further studied
in the future.
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The Authors Reply: We appreciate the interest of Dr Park1
and his group in our research2 and acknowledge the fact that
alternative explanations might be provided for the renal leak
of phosphate (P) observed in autosomal dominant polycystic
kidney disease (ADPKD). The mechanism suggested by Vogel
et al.3 offers a valid explanation for a renal leak of P in
polycystic kidney disease in rodents: a loss of expression of
the NaPi-2 cotransporter due to cyst development could
indeed account for a renal P wasting and hypophosphatemia
in such an animal model. However, this putative mechanism
implies that cyst development is the primary trigger for the
renal P loss: secondary decrease, and not increase in FGF23
levels, would thus be expected to occur. This is the reason
why we consider that cyst development alone cannot account
for the renal leak of P observed in our study. Furthermore,
Vogel et al. studied Han:SPRD rats that were in the late stage
of polycystic disease with advanced renal insufficiency,
whereas in our ADPKD patient average estimated glomerular
filtration rate was 94ml/min per 1.73m2. To our knowledge,
no data have been reported examining the localization of
NaPi-IIa or other phosphate transporters in the kidney from
ADPKD patients. This appears to be relevant as the relative
contribution of NaPi-IIa to renal phosphate handling in
humans is controversial.4 Therefore, several mechanisms may
account for the renal leak of phosphate observed in patients
with ADPKD, and further research is needed to unveil the
most important one.
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